Molecular Effect of Tobacco on Genetic, Epigenetic, and Metabolic Pathways During Cancer Progression.

Tobacco consumption remains a leading global health challenge, driving chronic diseases such as cancer, cardiovascular disorders, and metabolic dysfunction through intricate molecular mechanisms. This study investigates the multifaceted effects of tobacco exposure on genetic, epigenetic, and metabolic pathways, focusing on its role in carcinogenesis. Tobacco smoke, laden with carcinogens like benzopyrene, nitrosamines, and reactive oxygen species (ROS), induces genetic mutations and impairs DNA repair by downregulating tumor suppressor genes like tumor protein 53 (P53), ataxia-telangiectasia mutated (ATM), ataxia telangiectasia and Rad3-related (ATR), and poly (ADP-ribose) polymerase 1 (PARP1), leading to genomic instability and heightened cancer risk. Dysregulation of apoptosis-regulating genes B-cell lymphoma 2 (BCL-2), CL2 associated X (BAX), and cysteinyl aspartate specific proteinase 3 and 9 (CASPASE-3, CASPASE-9) further promotes tumor cell survival, while nicotine addiction genes cholinergic receptor nicotinic beta 3 subunit (CHRNB3), dopamine receptor D2 (DRD2), catechol-O-methyltransferase (COMT), and dopamine beta-hydroxylase (DBH) reinforce dependency via dopaminergic pathways. Metabolically, tobacco disrupts glycolysis, oxidative phosphorylation, and folate metabolism by altering cytochrome P450 family 2 subfamily A member 6 (CYP2A6), methylenetetrahydrofolate reductase (MTHFR), and hypoxia-inducible factor 1-alpha (HIF-1α) expression, resulting in insulin resistance, mitochondrial dysfunction, and lipid peroxidation, which exacerbate systemic diseases and cancer progression (Warburg effect). Epigenetic changes, including DNA methylation and histone modifications via histone deacetylase 1 (HDAC1), enhancer of zeste 2 polycomb repressive complex 2 subunits (EZH2), and suppressor of variegation 3-9 homolog 1 (SUV39H1), silence tumor suppressors cyclin-dependent kinase inhibitor 2A (CDKN2A), creating a long-term oncogenic imprint. Mitochondrial genes, mitochondrially encoded NADH: ubiquinone oxidoreductase core subunit 1 & 4 (MT-ND1 and MT-ND4) and mitochondrially encoded cytochrome c oxidase I (MT-CO1), suffer, reducing ATP synthesis and increasing ROS, which drives apoptosis evasion and inflammatory nuclear factor kappa B (NF-κB), interleukin 6 (IL-6), and tumor necrosis factor-α (TNF-α). This research uniquely integrates these molecular disruptions, emphasizing novel insights into metabolic reprogramming (CYP2A6, MTHFR, HIF-1α) and epigenetic mechanisms in tobacco-induced pathogenesis. Additionally, it explores impacts on stem cell genes, SRY-box transcription factor 2 (SOX2), octamer-binding transcription factor 4 (OCT4), and Nanog homeobox (NANOG), linking tobacco to cancer stem cell proliferation and metastasis (e.g., oral squamous cell carcinoma). The study also highlights tobacco's role in aging, telomere shortening - telomerase reverse transcriptase (TERT downregulation) - and thymic involution, accelerating immunosenescence and disease susceptibility. These findings underscore the need for targeted interventions, such as epigenetic therapies, metabolic reprogramming, and robust tobacco control policies, to mitigate the global burden of tobacco-related diseases. By providing a unified framework for understanding tobacco's molecular impact, this research advocates for precision medicine and public health strategies to address the pervasive effects of tobacco on human health.